ProCE Banner Activity

Proviral DNA Resistance Testing: Uses and Limitations When Switching ART

Clinical Thought

Here are my thoughts on the role of proviral DNA genotypic resistance testing for treatment-experienced people with HIV when switching ART in the setting of viral suppression, including when switching to long-acting ART.

Released: February 06, 2023

Expiration: February 05, 2024

Share

Faculty

José R. Arribas

José R. Arribas, MD

Professor of Medicine
Department of Medicine
Autónoma University School of Medicine
Head, Infectious Diseases Unit
Department of Internal Medicine
Hospital La Paz
Madrid, Spain

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

ViiV Healthcare